IC
BTAI icon

Ikarian Capital’s BioXcel Therapeutics BTAI Stock Holding History

Ikarian Capital’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,450
Closed -$1.33M – 140
2023
Q1 		$1.33M Buy
+4,450
New +$1.9M 0.3% 65
2021
Q2 		– Sell
-9,375
Closed -$6.47M – 229
2021
Q1 		$6.47M Hold
9,375
– – 0.22% 102
2020
Q4 		$6.93M Hold
9,375
– – 0.31% 77
2020
Q3 		$6.5M Buy
9,375
+75
+0.8% +$56.3K 0.47% 55
2020
Q2 		$7.89M Buy
9,300
+2,844
+44% +$1.85M 0.63% 50
2020
Q1 		$2.31M Buy
+6,456
New +$2.32M 0.17% 90

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ikarian Capital's BTAI Position: Q2 2023 in Review

Ikarian Capital sold out of BioXcel Therapeutics (BTAI) in Q2 2023, closing a stake of 8,313 shares — an estimated $2.48M sold.

Ikarian Capital first reported a position in BTAI in Q4 2019 and held it in 9 quarters. The position peaked at $15.5M in Q1 2020. 88 funds tracked by Wall St. Rank hold BTAI as of Q2 2023.

  • Ikarian Capital reported no remaining BioXcel Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ikarian Capital sold 8,313 BioXcel Therapeutics shares in Q2 2023, an estimated $2.48M.
  • Ikarian Capital first reported a position in BioXcel Therapeutics in Q4 2019 and held it in 9 quarters.
  • Ikarian Capital's BioXcel Therapeutics position peaked at $15.5M in Q1 2020.
  • 88 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.